Bruno Golding

Clinical Development Leader (Liver Indication Lead)

Roche Diagnostics

With over a decade of healthcare and life sciences experience, I am a clinical development professional specialising in non-invasive diagnostics, regulatory strategy, and clinical evidence generation across metabolic liver disease and oncology. In my role at Roche Diagnostics, I focus on the clinical development of innovative diagnostic solutions, with particular expertise in blood-based biomarkers and non-invasive approaches to transform risk stratification, disease monitoring, and therapeutic decision-making in metabolic dysfunction-associated steatotic liver disease (MASLD/MASH) and its progression to hepatocellular carcinoma (HCC). My background spans clinical evidence generation, translational science, and cross-functional leadership to drive IVD product development from early biomarker discovery through regulatory compliance. I am passionate about advancing scalable, non-invasive diagnostic tools that seamlessly bridge routine metabolic liver care with oncology care pathways.  

Updated: August 2026